Cargando…

Pharmacotherapy treatment of stimulant use disorder

Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral therapy and contingency management, are the main treatment modality for SUDs and no pharmacotherapy is curr...

Descripción completa

Detalles Bibliográficos
Autor principal: Liu, Mei T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582769/
https://www.ncbi.nlm.nih.gov/pubmed/34824959
http://dx.doi.org/10.9740/mhc.2021.11.347
_version_ 1784597060947804160
author Liu, Mei T.
author_facet Liu, Mei T.
author_sort Liu, Mei T.
collection PubMed
description Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral therapy and contingency management, are the main treatment modality for SUDs and no pharmacotherapy is currently FDA approved for this indication. Although some medications show promising data for the treatment of SUD, the evidence remains inconsistent, and the clinical application is limited due to the heterogenicity of the population and the lack of studies in patients with various comorbidities. Selection of pharmacotherapy treatment for methamphetamine intoxication, persistent methamphetamine-associated psychosis with methamphetamine use disorder, and cocaine use disorder in patients with co-occurring OUD are discussed in 3 patient cases.
format Online
Article
Text
id pubmed-8582769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-85827692021-11-24 Pharmacotherapy treatment of stimulant use disorder Liu, Mei T. Ment Health Clin Psychopharmacology Pearls Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral therapy and contingency management, are the main treatment modality for SUDs and no pharmacotherapy is currently FDA approved for this indication. Although some medications show promising data for the treatment of SUD, the evidence remains inconsistent, and the clinical application is limited due to the heterogenicity of the population and the lack of studies in patients with various comorbidities. Selection of pharmacotherapy treatment for methamphetamine intoxication, persistent methamphetamine-associated psychosis with methamphetamine use disorder, and cocaine use disorder in patients with co-occurring OUD are discussed in 3 patient cases. College of Psychiatric & Neurologic Pharmacists 2021-11-08 /pmc/articles/PMC8582769/ /pubmed/34824959 http://dx.doi.org/10.9740/mhc.2021.11.347 Text en © 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Psychopharmacology Pearls
Liu, Mei T.
Pharmacotherapy treatment of stimulant use disorder
title Pharmacotherapy treatment of stimulant use disorder
title_full Pharmacotherapy treatment of stimulant use disorder
title_fullStr Pharmacotherapy treatment of stimulant use disorder
title_full_unstemmed Pharmacotherapy treatment of stimulant use disorder
title_short Pharmacotherapy treatment of stimulant use disorder
title_sort pharmacotherapy treatment of stimulant use disorder
topic Psychopharmacology Pearls
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582769/
https://www.ncbi.nlm.nih.gov/pubmed/34824959
http://dx.doi.org/10.9740/mhc.2021.11.347
work_keys_str_mv AT liumeit pharmacotherapytreatmentofstimulantusedisorder